|
[PMID]: | 28823833 |
[Au] Autor: | Tang F; Yang TL; Zhang Z; Li XG; Zhong QQ; Zhao TT; Gong L |
[Ad] Endereço: | Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, PR China; Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou, PR China. |
[Ti] Título: | MicroRNA-21 suppresses ox-LDL-induced human aortic endothelial cells injuries in atherosclerosis through enhancement of autophagic flux: Involvement in promotion of lysosomal function. |
[So] Source: | Exp Cell Res;359(2):374-383, 2017 Oct 15. | [Is] ISSN: | 1090-2422 |
[Cp] País de publicação: | United States |
[La] Idioma: | eng |
[Ab] Resumo: | Atherosclerosis is a common pathological basis of cardiovascular disease and remains the leading cause of mortality. Endothelial cell (EC) injury and autophagy dysfunction have been proved to contribute to the development of atherosclerosis. Recently, accumulating evidence confirms that microRNAs (miRNAs) have emerged as vital regulators and fine-tuners of various pathophysiological cellular impacts and molecular signaling pathways involved in atherosclerosis. Herein, the objective of the present study was to explore the biological function of miR-21 in oxidized low-density lipoprotein (ox-LDL)-induced human aortic endothelial cells (HAECs) injury and the underlying molecular mechanism. The results showed that ox-LDL treatment significantly decreased HAECs viability, increased caspase-3 activity, apoptosis ratio and Bax protein expression, and reduced Bcl-2 protein expression resulting in EC injuries. Simultaneously, ox-LDL treatment obviously reduced miR-21 level in a time-and dose-dependent manner. Notably, ox-LDL-induced EC injuries were abolished by miR-21 mimics transfection. In addition, miR-21 mimics alleviated ox-LDL-induced impaired autophagic flux as illustrated by the increases in LC3-II/LC3-I ratio and Beclin-1 protein expression, and the decrease in p62 protein expression in HAECs. Moreover, ox-LDL suppressed the expressions of lysosomal membrane protein (LAMP1) and cathepsin D proteins, and attenuated cathepsin D activity in HAECs, leading to lysosomal dysfunction, while these effects were also blocked by miR-21 mimics. These findings indicated that miR-21 restored impaired autophagic flux and lysosomal dysfunction, thereby attenuating ox-LDL-induced HAECs injuries. |
[Mh] Termos MeSH primário: |
Autofagia/genética Células Endoteliais/efeitos dos fármacos Lipoproteínas LDL/farmacologia MicroRNAs/genética
|
[Mh] Termos MeSH secundário: |
Aorta/citologia Aorta/efeitos dos fármacos Aorta/metabolismo Autofagia/efeitos dos fármacos Beclina-1/genética Beclina-1/metabolismo Caspase 3/genética Caspase 3/metabolismo Catepsina D/genética Catepsina D/metabolismo Linhagem Celular Sobrevivência Celular/efeitos dos fármacos Células Endoteliais/citologia Células Endoteliais/metabolismo Regulação da Expressão Gênica Seres Humanos Glicoproteínas de Membrana Associadas ao Lisossomo/genética Glicoproteínas de Membrana Associadas ao Lisossomo/metabolismo Lisossomos/efeitos dos fármacos Lisossomos/metabolismo MicroRNAs/antagonistas & inibidores MicroRNAs/metabolismo Proteínas Associadas aos Microtúbulos/genética Proteínas Associadas aos Microtúbulos/metabolismo Mimetismo Molecular Oligorribonucleotídeos/genética Oligorribonucleotídeos/metabolismo Proteínas Proto-Oncogênicas c-bcl-2/genética Proteínas Proto-Oncogênicas c-bcl-2/metabolismo Proteína Sequestossoma-1/genética Proteína Sequestossoma-1/metabolismo Transdução de Sinais
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE |
[Nm] Nome de substância:
| 0 (BCL2 protein, human); 0 (BECN1 protein, human); 0 (Beclin-1); 0 (LAMP1 protein, human); 0 (Lipoproteins, LDL); 0 (Lysosome-Associated Membrane Glycoproteins); 0 (MAP1LC3A protein, human); 0 (MIRN21 microRNA, human); 0 (MicroRNAs); 0 (Microtubule-Associated Proteins); 0 (Oligoribonucleotides); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (SQSTM1 protein, human); 0 (Sequestosome-1 Protein); 0 (light chain 3, human); 0 (oxidized low density lipoprotein); EC 3.4.22.- (CASP3 protein, human); EC 3.4.22.- (Caspase 3); EC 3.4.23.5 (CTSD protein, human); EC 3.4.23.5 (Cathepsin D) |
[Em] Mês de entrada: | 1710 |
[Cu] Atualização por classe: | 171104 |
[Lr] Data última revisão:
| 171104 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 170822 |
[St] Status: | MEDLINE |
|
|
|